Goldman Sachs
KROS icon

Goldman Sachs’s Keros Therapeutics KROS Stock Holding History

Goldman Sachs’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.9M Sell
177,846
-46,633
-21% -$519K ﹤0.01% 4722
2026
Q1 		$2.48M Sell
224,479
-366,038
-62% -$5.65M ﹤0.01% 4351
2025
Q4 		$12M Sell
590,517
-734,966
-55% -$12.9M ﹤0.01% 2911
2025
Q3 		$21M Buy
1,325,483
+441,923
+50% +$6.53M ﹤0.01% 2218
2025
Q2 		$11.8M Buy
883,560
+142,954
+19% +$1.93M ﹤0.01% 2612
2025
Q1 		$7.55M Buy
740,606
+205,022
+38% +$2.38M ﹤0.01% 2948
2024
Q4 		$8.48M Buy
535,584
+179,920
+51% +$9.35M ﹤0.01% 2957
2024
Q3 		$20.7M Sell
355,664
-165,783
-32% -$8.19M ﹤0.01% 2045
2024
Q2 		$23.8M Buy
521,447
+263,079
+102% +$14.1M ﹤0.01% 1744
2024
Q1 		$17.1M Buy
258,368
+53,269
+26% +$3.16M ﹤0.01% 1977
2023
Q4 		$8.15M Buy
205,099
+105,040
+105% +$3.29M ﹤0.01% 2718
2023
Q3 		$3.19M Buy
100,059
+26,152
+35% +$976K ﹤0.01% 3379
2023
Q2 		$2.97M Buy
73,907
+11,647
+19% +$511K ﹤0.01% 3563
2023
Q1 		$2.66M Sell
62,260
-83,562
-57% -$4.22M ﹤0.01% 3624
2022
Q4 		$7M Sell
145,822
-30,542
-17% -$1.43M ﹤0.01% 2885
2022
Q3 		$6.63M Buy
176,364
+28,513
+19% +$988K ﹤0.01% 2888
2022
Q2 		$4.09M Buy
147,851
+20,020
+16% +$878K ﹤0.01% 3344
2022
Q1 		$6.95M Buy
127,831
+8,533
+7% +$438K ﹤0.01% 3037
2021
Q4 		$6.98M Buy
119,298
+67,389
+130% +$3.36M ﹤0.01% 3102
2021
Q3 		$2.05M Buy
51,909
+29,439
+131% +$1.05M ﹤0.01% 4177
2021
Q2 		$954K Buy
22,470
+16,108
+253% +$873K ﹤0.01% 4795
2021
Q1 		$392K Sell
6,362
-117,553
-95% -$7.45M ﹤0.01% 5277
2020
Q4 		$8.74M Buy
123,915
+106,197
+599% +$6.69M ﹤0.01% 2572
2020
Q3 		$683K Buy
+17,718
New +$703K ﹤0.01% 4308

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Goldman Sachs's KROS Position: Q2 2026 in Review

Goldman Sachs reduced its Keros Therapeutics (KROS) stake by 21% in Q2 2026, selling an estimated $519K and leaving 177,846 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #4722.

Goldman Sachs first reported a position in KROS in Q3 2020 and has held it in 24 quarters since. The position peaked at $23.8M in Q2 2024. 133 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Goldman Sachs held 177,846 shares of Keros Therapeutics worth $1.9M as of Q2 2026.
  • Goldman Sachs sold 46,633 Keros Therapeutics shares in Q2 2026, an estimated $519K.
  • Keros Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4722 holding.
  • Goldman Sachs first reported a position in Keros Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Goldman Sachs's Keros Therapeutics position peaked at $23.8M in Q2 2024.
  • 133 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.